生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK1161 生物科技

未开盘 12-15 16:00:00

5,833.064

-326.819

-5.31%

最高6,162.985	最低5,817.257	成交量1.95亿
今开6,160.303	昨收6,159.883	日振幅5.61%
总市值0.00	流通市值0.00	总股本0.00
成交额77.33亿	换手率--	流通股本0.00
市净率8.030538	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"BK1161","market":"HK","secType":"PLATE","nameCN":"生物科技","latestPrice":5833.064,"timestamp":1765786113871,"preClose":6159.883,"halted":0,"volume":195073241,"delay":0,"changeRate":-0.053056,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-326.818848,"latestTime":"12-15 16:00:00","open":6160.3027,"high":6162.9854,"low":5817.2573,"amount":7732909234,"amplitude":0.056126,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765848600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1765762200000,1765771200000],[1765774800000,1765785600000]],"pbRate":8.030538,"peRate":-82.449697,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK1161","defaultTab":"news","newsList":[{"id":"2591644571","title":"诺诚健华：截至2025年11月28日A股股东户数约1.79万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2591644571","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591644571?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:43","pubTimestamp":1765806180,"startTime":"0","endTime":"0","summary":"证券日报网讯12月15日，诺诚健华在互动平台回答投资者提问时表示，截至2025年11月28日公司A股股东户数约为1.79万户。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153592007823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","159982","BK1161","BK1574","688428","09969","399300"],"gpt_icon":0},{"id":"2591641505","title":"荣昌生物：第二届董事会第三十二次会议决议公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2591641505","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591641505?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:05","pubTimestamp":1765803918,"startTime":"0","endTime":"0","summary":"证券日报网讯12月15日晚间，荣昌生物发布公告称，公司第二届董事会第三十二次会议审议通过《关于以集中竞价交易方式回购公司股份方案的议案》等多项议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153591974866.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1969619763.USD","LU1064131003.USD","BK1574","BK1583","BK0239","LU2148510915.USD","LU2488822045.USD","688331","LU1064130708.USD","09995","BK1161","LU2328871848.SGD"],"gpt_icon":0},{"id":"2591142649","title":"科伦博泰生物-B(06990)：三款产品获纳入国家医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2591142649","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591142649?lang=zh_cn&edition=full","pubTime":"2025-12-15 21:03","pubTimestamp":1765803821,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B(06990)发布公告，本公司三款产品，即ADC Sacituzumab Tirumotecan(sac-TMT，亦称SKB264/MK-2870)(商品名：佳泰莱®)、西妥昔单抗N01注射液(前称A140)(商品名：达泰莱®)及Tagitanlimab(亦称A167)(商品名：科泰莱®)，已获纳入国家医疗保障局及中国人力资源和社会保障部于2025年12月7日公布的国家医保目录。值得注意的是，ADC Sacituzumab Tirumotecan有两项适应症获纳入国家医保目录。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科伦博泰生物-B(06990)：三款产品获纳入国家医保目录","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2591764679","title":"维立志博-B(09887)拟实施H股全流通计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2591764679","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591764679?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:42","pubTimestamp":1765802564,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维立志博-B(09887)发布公告，于2025年12月15日，本公司已就拟实施H股全流通(H股全流通)向中国证监会提交备案材料，以转换合共4439.16万股本公司未上市股份(未上市股份)为本公司H股(占于本公告日期本公司已发行股本总额1.99亿股股份约22.32%)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HK0000252160.HKD","HK0000252152.HKD","HK0000500386.USD","BK1161","09887"],"gpt_icon":0},{"id":"2591459856","title":"科济药业-B(02171)12月15日斥资790.76万港元回购52.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2591459856","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591459856?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:00","pubTimestamp":1765800031,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B(02171)发布公告，于2025年12月15日斥资790.76万港元回购52.2万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381748.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","02171","BK1585","BK1574","BK1161"],"gpt_icon":0},{"id":"2591264308","title":"康哲药业(00867)：创新药口服小分子JAK1抑制剂Povorcitinib 纳入突破性治疗品种名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2591264308","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591264308?lang=zh_cn&edition=full","pubTime":"2025-12-15 19:49","pubTimestamp":1765799362,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康哲药业 发布公告，集团旗下德镁医药有限公司拥有相关许可权利的创新口服JAK1抑制剂povorcitinib已获中国国家药品监督管理局药品评审中心批准纳入突破性治疗品种名单，拟定适应症为成人患者非节段型白癜风。Povorcitinib目前正在海外若干国家进行非节段型白癜风、中重度化脓性汗腺炎和结节性痒疹的3期临床试验。本次该产品获纳入突破性治疗药物品种名单，有望加速其在中国大陆的研发与审评进程。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381734.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["00867","BK1574","SG9999015952.SGD","IE00BMCWC346.EUR","BK1191","IE00BVYPNQ40.USD","SG9999015945.SGD","SG9999004220.SGD","LU2488822045.USD","IE00BYV24P56.USD","IE00BVYPNP33.GBP","SG9999015978.USD","IE00BGHQDM52.EUR","159992","06978","SG9999015986.USD","BK1593","BK1161"],"gpt_icon":0},{"id":"2591648625","title":"争议药物\"九期一\"获新生？复星医药14亿元收购绿谷医药重启临床与商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2591648625","media":"蓝鲸财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591648625?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:51","pubTimestamp":1765795877,"startTime":"0","endTime":"0","summary":"此次收购案后，复星医药方面表示，甘露特钠胶囊重新开展商业化生产和销售前，还需补充完成目前尚在开展的上市后确证性临床试验并获得国家药品审评部门批准。本次收购完成后，复星医药将携绿谷医药团队在药品审评部门的指导下，有序严谨推进上市后确证性临床试验，以期尽快实现获批；并适时开展相关适应症的国际多中心临床试验，惠及更多阿尔茨海默病患者。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1765795546434638047","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0183","BK0175","BK0188","BK1191","BK1515","BK0028","BK0187","BK0196","BK0060","BK1593","BK0012","600196","09939","BK1161","02196","BK0096","BK1574","BK0239","159938"],"gpt_icon":1},{"id":"2591100736","title":"19种创新药“入编”商保目录 险企仍面临定价、合规等挑战","url":"https://stock-news.laohu8.com/highlight/detail?id=2591100736","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591100736?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:09","pubTimestamp":1765793340,"startTime":"0","endTime":"0","summary":"　　12月13日，全国医疗保障工作会议在北京召开。会议明确提出，2026年要支持商业健康保险发展，健全多层次医疗保障体系，并特别强调要“积极落地商保创新药品目录”，在个人充分授权和确保数据安全基础上，为有需要的商业健康保险产品提供“医保+商保”一站式清分结算服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/money/insurance/bxdt/2025-12-15/doc-inhawtsc3977664.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxdt/2025-12-15/doc-inhawtsc3977664.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1574","BK1161","159992"],"gpt_icon":0},{"id":"2591612068","title":"复星医药：控股子公司拟出资14.12亿元投资绿谷医药","url":"https://stock-news.laohu8.com/highlight/detail?id=2591612068","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591612068?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:43","pubTimestamp":1765791813,"startTime":"0","endTime":"0","summary":"每经AI快讯，12月15日，复星医药(600196.SH)公告称，公司控股子公司复星医药产业拟出资共计14.12亿元投资绿谷医药，包括受让部分股权和认缴新增注册资本。完成后，公司将通过复星医药产业及SPV合计持有绿谷医药53%的股权。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512153591807093.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512153591807093.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1593","BK1191","BK0012","BK0096","BK1574","BK1515","09939","BK0060","BK0188","BK0175","BK0239","BK0196","600196","BK0183","BK0187","BK0028","02196","159938","BK1161"],"gpt_icon":0},{"id":"2591625600","title":"3家药企因下游合作方“不合规交易行为”公开致歉","url":"https://stock-news.laohu8.com/highlight/detail?id=2591625600","media":"一拾药讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591625600?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:35","pubTimestamp":1765791351,"startTime":"0","endTime":"0","summary":"近日，河南省医药集中采购平台公布了3家药企发布的致歉声明。分别为哈尔滨誉衡制药、吉林四环制药、珠海经济特区粤康医药三家企业的公开致歉声明，原因均为其配送商或代理商存在不合规交易行为。珠海经济特区粤康医药则因其注射用头孢呋辛钠的代理商违规，被预评为“特别严重失信”。这一现象反映出，在医药招采信用评价制度下，药企对合作方的合规管理已与其自身信用直接挂钩，下游一旦违规，药企也难逃责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215183743a44dbf01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215183743a44dbf01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","01477","BK1161","BK1191","09939","00460","BK1574","BK1600","BK1515"],"gpt_icon":0},{"id":"2591054614","title":"荣昌生物(688331.SH)拟以2000万元至4000万元回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2591054614","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591054614?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:32","pubTimestamp":1765791179,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(688331.SH)发布公告，公司拟以2000万元至4000万元回购股份，回购股份价格不超过95元/股，回购的股份拟用于员工持股计划或股权激励。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381592.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","LU1064130708.USD","BK0239","LU1064131003.USD","LU2328871848.SGD","688331","LU2488822045.USD","LU1969619763.USD","LU2148510915.USD","09995","BK1161","BK1574"],"gpt_icon":0},{"id":"2591614559","title":"拨康视云-B(02592)向美国药管局提交有关CBT-199的新药临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2591614559","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591614559?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:15","pubTimestamp":1765790138,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B 发布公告，于2025年12月15日，本公司全资附属公司ADS Therapeutics LLC向美国食品及药物管理局提交有关CBT-199的新药临床试验申请。诚如本公司日期为2025年6月24日的招股章程所披露，本集团已于2023年在中国开始 CBT-199的药物发现过程。CBT-199已自2023年6月起于临床前动物研究中进行安全性和耐受性评估，有关研究预期将有助于未来的临床试验。提交新药临床试验申请为美国药管局启动药物审查程序以及取得监管批准以展开CBT-199的临床试验的第一步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CBT","BK4090","02592","BK1161"],"gpt_icon":0},{"id":"2591649007","title":"医药日报：复宏汉霖新适应症获优先审评，君实生物双抗ADC出海获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2591649007","media":"药融链接","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591649007?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:06","pubTimestamp":1765789608,"startTime":"0","endTime":"0","summary":"君实生物双抗ADC获FDA临床试验批准，国际化研发取得新进展。02产品注册与审批复宏汉霖：其产品斯鲁利单抗注射液新增适应症的上市申请已获受理，并被纳入优先审评程序。04国际合作与出海君实生物：其针对EGFR/HER3的双特异性抗体偶联药物用于治疗晚期实体瘤的临床试验申请，已获得美国FDA批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215175631a44d99ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215175631a44d99ba&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","BK1574","BK1583","09939","01877","BK1515","02696","BK1161"],"gpt_icon":0},{"id":"1122759110","title":"歌礼制药-B公布美国I期研究Asc50的积极顶线结果，这是一种潜在的最佳口服小分子IL-17抑制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1122759110","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122759110?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:00","pubTimestamp":1765789225,"startTime":"0","endTime":"0","summary":"歌礼制药-B公布了美国I期研究Asc50的积极顶线结果，这是一种潜在的最佳口服小分子IL-17抑制剂","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1161","01672","BK1574"],"gpt_icon":0},{"id":"2591611929","title":"香港医疗设备采购商柏威医药(AED.US)申请美股IPO，拟筹资700万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591611929","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591611929?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:55","pubTimestamp":1765788951,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，总部位于香港的医疗设备和软件采购商柏威医药于上周四向美国证券交易委员会提交文件，计划通过首次公开募股筹集至多700万美元资金。该公司计划以每股7至9美元的价格发行90万股股票，筹资700万美元。按拟议发行区间的中值计算，柏威医药的市值将达到8700万美元。这家总部位于香港的公司成立于2003年，在截至2025年3月31日的12个月内录得营业收入2500万美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","BK1515","BK1574","09939","159873","BK1161"],"gpt_icon":0},{"id":"2591116096","title":"歌礼制药-B(01672)：有望成为同类最佳口服小分子IL-17抑制剂ASC50美国I期研究取得积极的顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2591116096","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591116096?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:49","pubTimestamp":1765788597,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，ASC50在美国开展的一项随机、双盲、安慰剂对照的I期临床试验取得积极顶线结果，该试验是在健康受试者中进行的单剂量递增研究，旨在评估ASC50的安全性、耐受性、药代动力学及外周循环的白细胞介素-17A靶向结合特征。ASC50为歌礼自主研发的口服小分子IL-17靶向抑制剂，IL-17在银屑病等多种自身免疫及炎症性疾病中已获充分的生物学验证并具备成熟商业价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","BK1191","BK1515","BK1574","01477","BK1161"],"gpt_icon":0},{"id":"2591264799","title":"每日卖空追踪 | 维立志博-B 12月15日卖空量成交1.86万股，卖空比例为6.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591264799","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591264799?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787440,"startTime":"0","endTime":"0","summary":"维立志博-B北京时间12月15日，跌2.35%，卖空量成交1.86万股，较上一交易日减少51.18%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163643a6a45a4d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163643a6a45a4d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000500386.USD","HK0000252152.HKD","BK1161","09887","HK0000252160.HKD"],"gpt_icon":0},{"id":"2591661614","title":"每日卖空追踪 | 科伦博泰生物-B 12月15日卖空量成交5.15万股，卖空比例为4.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591661614","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591661614?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787437,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B北京时间12月15日，跌8.21%，卖空量成交5.15万股，较上一交易日减少72.24%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163625a44d4363&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163625a44d4363&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2591625981","title":"每日卖空追踪 | 中国抗体-B 12月15日卖空量成交23.52万股，卖空比例为6.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591625981","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591625981?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787433,"startTime":"0","endTime":"0","summary":"中国抗体-B北京时间12月15日，跌0.67%，卖空量成交23.52万股，较上一交易日减少48.11%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163526a44d4224&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163526a44d4224&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","03681","BK1574"],"gpt_icon":0},{"id":"2591100641","title":"每日卖空追踪 | 拨康视云-B 12月15日卖空量成交5.7万股，卖空比例为1.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591100641","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591100641?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787431,"startTime":"0","endTime":"0","summary":"拨康视云-B北京时间12月15日，跌19.51%，卖空量成交5.7万股，较上一交易日增加46.15%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163501a44d41af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163501a44d41af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02592"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.0533},{"period":"3month","weight":-0.0306},{"period":"6month","weight":0.0809},{"period":"1year","weight":0.2833},{"period":"ytd","weight":0.2776}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"name":"BK1161","nameEN":"BK1161"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK1161,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK1161)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK1161)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}